GO
Loading...

GlaxoSmithKline PLC

More

  • Lightning Round: Altria, Delta, VMware and More Wednesday, 12 Mar 2008 | 7:29 PM ET

    Cramer makes the call on viewers' favorite stocks.

  • Big Pharma: Market Medicine? Monday, 3 Mar 2008 | 4:06 PM ET

    With Warren Buffett nosing around Big Pharma, investors are starting to wonder if drug makers might be the remedy to what ails this market.

  • In a series of exclusive live appearances on CNBC's Squawk Box this morning, Warren Buffett told us that by a "common sense definition", the U.S. economy is already in a recession, even if it hasn't met the technical definition of two consecutive quarters of negative growth.  He restated, however, his view that over the long-run the U.S. economy will do fine and that each generation will live better than the one before it.

  • Glaxo Wins FDA Priority Review for Blood Drug Monday, 3 Mar 2008 | 11:04 AM ET

    GlaxoSmithKline's experimental platelet-boosting drug Promacta has been granted priority review by U.S. health regulators, boosting prospects for its early launch, Europe's biggest drugmaker said on Monday.

  • Drug Money Still A "Healthy Flow" To Democrats Monday, 3 Mar 2008 | 9:29 AM ET

    On the eve of the make-or-break Texas-Ohio primaries for Sen. Hillary Clinton, she remains in first place in at least one "poll." The Center for Responsive Politics has updated its list of top pharmaceuticals/health products-industry money recipients based on the most recent campaign finance reports and the former First Lady edges out Sen. Barack Obama...

  • Glaxo's Tykerb Goes Head-to-Head with Herceptin Friday, 29 Feb 2008 | 5:10 AM ET

    GlaxoSmithKline's new breast cancer drug Tykerb is to go head-to-head with Genentech's blockbuster Herceptin to see whether one is better or if patients should get both.

  • Boxes of Kraft Macaroni and Cheese are seen Wednesday, April 19, 2006, in Milwaukee. Kraft Foods Inc. releases first-quarter earnings after the bell.  (AP Photo/Morry Gash)

    Warren Buffett's Berkshire Hathaway has accumulated an 8.6% stake in Kraft Foods, totaling over 132 million shares as of the end of the fourth quarter on December 31. That stake was worth $4.3 billion at that time. At today's closing price of $29.31, it's worth about $3.9 billion.  EXPLORE WARREN BUFFETT'S INVESTMENTS WITH OUR NEW BERKSHIRE HATHAWAY PORTFOLIO TRACKER

  • Market Insider/Friday Look Ahead  Thursday, 14 Feb 2008 | 8:24 PM ET

    Friday's markets will likely continue to be vulnerable to credit worries. There are a few economic data points including import prices and the Empire State survey, both at 8:30 a.m. TIC data from the Treasury is released at 9 a.m. and industrial production comes out at 8:15 a.m. Consumer sentiment is due at 10 a.m.

  • Dow Drops 175 Thursday, 14 Feb 2008 | 6:26 PM ET

    Federal Reserve Chairman Ben Bernanke said the economy should grow at a slow pace before recovering later in the year. What's the word on the Street?

  • These Days, Even Minor News Can 'Buffett' Stocks Tuesday, 12 Feb 2008 | 2:21 PM ET
    Broker works the trading floor at the New York Stock Exchange.

    The markets had a Warren Buffett rally on Tuesday, but tomorrow's news could just as easily send stocks plummeting again.

  • Your First Move For Friday Feb. 8th Thursday, 7 Feb 2008 | 7:17 PM ET

    Here's our Fast Money Final Trade. Our gang gives you tomorrow's best trades, right now!

  • Glaxo Profit Falls on Sliding Diabetes Drug Sales Thursday, 7 Feb 2008 | 12:57 PM ET
    Glaxo Smith Kline

    GlaxoSmithKline forecast lower 2008 earnings due to falling sales of diabetes drug Avandia and increased generic competition, sending shares in Europe's biggest drugmaker down 7.6 percent on Thursday.

  • Glaxo's Avandia Hits The Bottom Line--Hard Thursday, 7 Feb 2008 | 12:43 PM ET

    Shares of GlaxoSmithKline this morning are getting hammered because the company announced it expects earnings per share to fall by a mid-single digit percentage this year. Analysts thought they'd grow by three percent.

  • Market Insider/Thursday Look Ahead Wednesday, 6 Feb 2008 | 10:53 PM ET

    Cisco's downbeat earnings comments could make a dent in stocks Thursday morning. Ahead of the opening bell, investors will also be watching rate meetings by the European Central Bank and the Bank of England.

  • Diabetes Drug Safety: Has Another Red Flag Been Raised? Wednesday, 6 Feb 2008 | 3:07 PM ET

    Reaction to part of a big government-sponsored diabetes drug study being halted over fatalities is pouring in from several corners. The American Diabetes Association put out a press release saying it "strongly encourages people with diabetes not to alter their course of treatment without first consulting with their health care team...

  • Drug Stocks: Real Downers And At A Two-Year Low Tuesday, 5 Feb 2008 | 4:29 PM ET

    Yes, it was a big down day for equities, but I wanted to call attention to the fact that according to one of our resident stock gurus, Robert Hum, the Amex Pharmaceutical Index (you can see the 15 stocks that make up the so-called DRG here) closed at a two-year low today.

  • S&P Stock Screen Uncovers "What Buffett Would Buy" Tuesday, 5 Feb 2008 | 2:49 PM ET
    The new Apple iPhone is seen Friday, June 29, 2007 in New York.  (AP Photo/Jason DeCrow)

    Standard and Poor's has just released the results of its twice-a-year stock screen, designed to find Warren Buffett-style stocks. The new list features several tech stocks, including Apple, as well as a number of names from Europe and Asia.  But some key Buffett criteria aren't taken into account by the screen.

  • Glaxo's Avandia Leak: Who Really Broke Embargo? Wednesday, 30 Jan 2008 | 4:59 PM ET
    GlaxoSmithKline's Avandia

    At 1 pm ET today the embargo was supposed to lift on an article in the scientific journal "Nature" that we got advanced word on early this morning. We were set to post the write-through about it at that time on our web site.

  • Avandia Study Results Were Leaked Early to Glaxo Wednesday, 30 Jan 2008 | 12:46 PM ET
    The company logo of GlaxoSmithKline, is seen on the headquarters building in London, Wednesday May 10, 2006. GlaxoSmithKline PLC said Wednesday it has been granted a High Court injunction against animal rights activists who sent threats to the drugmaker's shareholders, barring them from sending more letters or revealing private information about the investors. (AP Photo/Alastair Grant)

    The scientific journal Nature reported today that a peer-reviewer for The New England Journal of Medicine leaked key study results on GlaxoSmithKline's diabetes drug Avandia to the company weeks before they were published.

  • Pharma Analyst: Stocks Healthy Despite Bad News Thursday, 17 Jan 2008 | 3:55 PM ET
    Eli Lilly

    For the second time this week, big pharma is taking a beating from critical reports about medications. This time, it's antidepressants. But one analyst thinks the drag on shares is overdone -- and names "exciting" pharma stocks.